[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":73,"collaborators":20,"id":75,"slug":20,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":20,"enrollmentInfo":84,"targetDuration":20,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":20,"overallStatus":46,"whyStopped":20,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Imricor Medical Systems","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-Randomized","EXPERIMENTAL","All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0",[13],"Device: Vision-MR Ablation Catheter 2.0",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Vision-MR Ablation Catheter 2.0","Catheter ablation of ventricular tachycardia",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Kate Lindborg, Phd","CONTACT","9528188400","kate.lindborg@imricor.com",[28,44,59],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Herzzentrum Leipzig","NOT_YET_RECRUITING","Leipzig","Saxony","04289","Germany",{"type":36,"coordinates":37},"Point",[38,39],12.37129,51.33962,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":20,"phoneExt":20,"email":20},"Sebastian Hilbert",{"facility":45,"status":46,"city":47,"state":20,"zip":20,"country":48,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Amsterdam UMC","RECRUITING","Amsterdam","Netherlands",{"type":36,"coordinates":50},[51,52],4.88969,52.37403,{"lat":52,"lon":51},[55],{"name":56,"role":24,"phone":57,"phoneExt":20,"email":58},"Michiel Kemme","+31 020-4442244","m.kemme@amsterdamumc.nl",{"facility":60,"status":30,"city":61,"state":20,"zip":62,"country":48,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"HagaZiekenhuis","The Hague","2545 AA",{"type":36,"coordinates":64},[65,66],4.29861,52.07667,{"lat":66,"lon":65},[69,71],{"name":70,"role":24,"phone":20,"phoneExt":20,"email":20},"Ivo Van Der Bilt, MD, PhD",{"name":72,"role":24,"phone":20,"phoneExt":20,"email":20},"Hemanth Ramanna, MD, PhD",{"type":74,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100481038",false,"NCT05543798","VT Ablation in the iCMR","Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia","VISABL-VT","Inclusion Criteria:\n\n* Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy)\n* Documented (ECG\u002FEGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure\n* Diagnosis of Ischemic Cardiomyopathy\n* AAD therapy refractory, contraindicated, not tolerated, or not desired\n* 18 years or older\n\nExclusion Criteria:\n\n* Implanted with non-MR compatible medical devices or contraindicated for an MRI\n* Presence of intracardiac thrombus (verified via CT\u002FMRI\u002FTEE\u002FTTE within 48 hours of procedure - or at start of procedure)\n* Thrombocytopenia or coagulopathy\n* Mechanical mitral and\u002For aortic valve precluding access to the left ventricle\n* Severe aortic stenosis\n* Myocardial infarction requiring stent implantation within 90 days of procedure\n* Previous cardiac surgery within 60 days of procedures\n* Known\u002Funcontrolled stroke risks\n* Class IV Heart Failure\n* Ejection Fraction (EF) \\\u003C 25%\n* Patients with a glomerular filtration rate (GFR) \\\u003C 30\n* Women who are pregnant\n* Allergy to contrast agents (e.g., Gadolinium)\n* Active infection\n* Known or suspected myxoma\n* Unstable angina\n* Patients who do not tolerate anticoagulation therapy\n* Previous intertribal septal patch or prosthetic atrial septal defect closure device\n* Life expectancy \\\u003C 12 months\n* Enrollment in another study without sponsor approval","ALL","18 Years",{"count":85,"type":86},64,"ESTIMATED","INTERVENTIONAL",[89],"NA","The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.",[92],"Ventricular Tachycardia","2026-01-06",{"date":95,"type":96},"2026-01-08","ACTUAL",{"date":98,"type":96},"2025-04-10",{"date":100,"type":86},"2027-06",{"name":5,"class":6},3]